These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29288467)

  • 1. Prognostic factors of regrowth in nonfunctioning pituitary tumors.
    Raverot G; Vasiljevic A; Jouanneau E
    Pituitary; 2018 Apr; 21(2):176-182. PubMed ID: 29288467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists are effective in inhibiting proliferation of progenitor/stem-like cells isolated from nonfunctioning pituitary tumors.
    Peverelli E; Giardino E; Treppiedi D; Meregalli M; Belicchi M; Vaira V; Corbetta S; Verdelli C; Verrua E; Serban AL; Locatelli M; Carrabba G; Gaudenzi G; Malchiodi E; Cassinelli L; Lania AG; Ferrero S; Bosari S; Vitale G; Torrente Y; Spada A; Mantovani G
    Int J Cancer; 2017 Apr; 140(8):1870-1880. PubMed ID: 28120505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy for non-functioning pituitary tumors-a critical approach.
    Tampourlou M; Karapanou O; Vassiliadi DA; Tsagarakis S
    Hormones (Athens); 2019 Jun; 18(2):117-126. PubMed ID: 30368687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
    Greenman Y; Cooper O; Yaish I; Robenshtok E; Sagiv N; Jonas-Kimchi T; Yuan X; Gertych A; Shimon I; Ram Z; Melmed S; Stern N
    Eur J Endocrinol; 2016 Jul; 175(1):63-72. PubMed ID: 27150495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of clinically nonfunctioning pituitary adenomas].
    Alameda Hernando C; Lahera Vargas M; Varela Da Costa C
    Endocrinol Nutr; 2010 Feb; 57(2):71-81. PubMed ID: 20227355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological characteristics of reoperated regrowing clinically nonfunctioning pituitary tumor cases in comparison with initial surgical cases.
    Ishida A; Inoshita N; Tanabe N; Takano K; Tanaka-Mizuno S; Kato M; Yoshimoto H; Shiramizu H; Matsuoka G; Yamada S
    Front Endocrinol (Lausanne); 2024; 15():1400671. PubMed ID: 38863935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current medical treatment and perspective in gonadotroph tumors.
    Even-Zohar N; Greenman Y
    Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101685. PubMed ID: 35871905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability in quantitative expression of receptors in nonfunctioning pituitary macroadenomas--an opportunity for targeted medical therapy.
    Babu A; Luque RM; Glick R; Utset M; Fogelfeld L
    Endocr Pract; 2014 Jan; 20(1):15-25. PubMed ID: 24013975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
    Ilie MD; Raverot G
    J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32735647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma.
    Dekkers OM; Pereira AM; Roelfsema F; Voormolen JH; Neelis KJ; Schroijen MA; Smit JW; Romijn JA
    J Clin Endocrinol Metab; 2006 May; 91(5):1796-801. PubMed ID: 16507632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Younger age is a risk factor for regrowth and recurrence of nonfunctioning pituitary macroadenomas: Results from a single Australian centre.
    Watts AK; Easwaran A; McNeill P; Wang YY; Inder WJ; Caputo C
    Clin Endocrinol (Oxf); 2017 Sep; 87(3):264-271. PubMed ID: 28467632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.
    Greenman Y; Tordjman K; Osher E; Veshchev I; Shenkerman G; Reider-Groswasser II; Segev Y; Ouaknine G; Stern N
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):39-44. PubMed ID: 15963059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence.
    Losa M; Mortini P; Barzaghi R; Ribotto P; Terreni MR; Marzoli SB; Pieralli S; Giovanelli M
    J Neurosurg; 2008 Mar; 108(3):525-32. PubMed ID: 18312100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.
    Yedinak CG; Cetas I; Ozpinar A; McCartney S; Dogan A; Fleseriu M
    Endocrine; 2016 Oct; 54(1):191-197. PubMed ID: 27460005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
    Melmed S; Sternberg R; Cook D; Klibanski A; Chanson P; Bonert V; Vance ML; Rhew D; Kleinberg D; Barkan A
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4405-10. PubMed ID: 15827109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas.
    Dekkers OM; Pereira AM; Romijn JA
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3717-26. PubMed ID: 18682516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
    Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
    Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.